TY  - JOUR
T1  - HIv drugs and malaria
AU  - Friedrich MJ
Y1  - 2013/01/16
N1  - 10.1001/jama.2012.206200
JO  - JAMA
SP  - 223
EP  - 223
VL  - 309
IS  - 3
N2  - 
In the open-label randomized trial, the participants—170 children aged 5 months to 5 years in Uganda who were infected with HIV—received antimalarial drugs and either of 2 anti-HIV therapies: the protease inhibitors lopinavir and ritonavir or non–nucleoside reverse transcriptase inhibitors (NNRTIs). Although neither regimen lowered the children's risk of developing malaria during the first 6 months of the study, risk of recurrence of malaria after successful treatment with the antimalarial drug artemether-lumefantrine was reduced by 41% in the group receiving protease inhibitors compared with those receiving NNRTIs. There was an increase in serious adverse events in the group receiving protease inhibitors.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.206200
UR  - http://dx.doi.org/10.1001/jama.2012.206200
ER  -